BioCardia
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Contact Us

Press & News

Shortcuts: 2017  2016  2015  2014 

2017
Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial
BioCardia to Present at the 9th Annual Biotech Showcase in San Francisco
2016
CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers
BioCardia receives another US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program
BioCardia receives US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program
BioCardia Chairman of the Board Letter to Shareholders
BioCardia Closes Merger with Tiger X Medical, Inc.
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure
BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure
BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium
BioCardia®, Inc. Announces Two Presentations Related to Cardiamp Cell Therapy at Cardiovascular Research Technologies in Washington DC
BioCardia Announces Upcoming Cell Therapy Presentations at Cardiovascular Research Technologies Conference

2015
BioCardia to Present at 2015 Stem Cell Meeting on the Mesa
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering

2014
Cover story in Bioworld Today: BioCardia pumped: FDA clears the way for phase III heart failure experiment
BioCardia, Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients
CellProThera® and BioCardia® Partner on Phase II Trial to Study CellProThera’s Protheracytes® CD34+ Cells as Delivered by BioCardia’s Helix™ Transendocardial Delivery System
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System
RECARDIO Clinical Trial Doses First Patient
BioCardia Receives CE Mark for Morph Access Pro™ Steerable Introducer
BioCardia Receives CE Mark for New Helix™ Transendocardial Delivery Catheter